MedTrace Logo

Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia

NCT00640926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2016-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).

Conditions

  • Community-Acquired Pneumonia (CAP)

Interventions

DRUG

Radezolid

300 mg/day, orally for 7-10 days

DRUG

Radezolid

450 mg/day orally for 7-10 days

DRUG

Radezolid

900 mg/day orally for 7-10 days

Sponsors & Collaborators

  • Melinta Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • United States
  • Canada
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640926 on ClinicalTrials.gov